Kuros Biosciences AG (SWX:KURN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 858.72M |
| Revenue (ttm) | 115.82M |
| Net Income (ttm) | 2.02M |
| Shares Out | 39.18M |
| EPS (ttm) | 0.05 |
| PE Ratio | 424.52 |
| Forward PE | 82.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,205 |
| Average Volume | 164,988 |
| Open | 22.00 |
| Previous Close | 22.18 |
| Day's Range | 21.60 - 22.20 |
| 52-Week Range | 21.24 - 34.20 |
| Beta | 0.79 |
| RSI | 38.26 |
| Earnings Date | Aug 13, 2026 |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone graft... [Read more]
News
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product ...
Kuros Biosciences AG Earnings Call Transcript: H2 2025
Achieved first-time profitability in 2025 with 72% revenue growth and strong operational execution. Guidance for 2026 targets at least 35% revenue growth and 14% adjusted EBITDA margin, with continued expansion in spine, extremities, and trauma segments.
Kuros Biosciences AG Earnings Call Transcript: H1 2025
Achieved 78% revenue growth and first operating profit in H1 2025, driven by strong execution in spine and extremities, Medtronic partnership, and new product launches. Guidance for at least 60% annual growth is maintained, with minimal tariff impact expected and U.S. production set for H2 2026.
Kuros Biosciences AG Transcript: CMD 2025
Focused on MagnetOs, the company achieved rapid revenue growth, expanded globally, and invested in operational efficiency and clinical evidence. New product launches and entry into extremities and trauma markets support ambitious mid-term sales targets, while strategic partnerships and a robust R&D pipeline drive future growth.
Kuros Biosciences AG Earnings Call Transcript: H2 2024
2024 saw record revenue and EBITDA growth, driven by U.S. and international expansion, a strategic Medtronic partnership, and operational efficiency. Guidance calls for at least 60% revenue growth in 2025, with a strong cash position and no debt supporting further organic and selective inorganic growth.
Kuros Biosciences AG Earnings Call Transcript: H1 2024
Revenue grew 148% year-over-year in H1 2024, driven by MagnetOs and strong U.S. performance. Adjusted EBITDA margin reached 12.5%, with no debt and robust cash reserves. Outlook remains positive, with continued expansion in both spine and non-spine markets.